Payment overview · 2025
General Payments
$2,045.78
109 reported records · 25 companies
Healthcare provider profile · identity verified
John Wallace Neville, MD
Allopathic & Osteopathic Physicians|Family Medicine · HURRICANE, WV · NPI 1265492797
Verified facts
What the public records show
CMS Open Payments records show John Wallace Neville, MD received $2,045.78 in general payments during 2025 across 109 reported records.
Novo Nordisk Inc accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 751 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $502.62 | 24.6% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.52 | 8.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.45 | 8.1% | 10 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $149.79 | 7.3% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $134.83 | 6.6% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.11 | 5.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.48 | 5.2% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $98.89 | 4.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.45 | 4.6% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $62.39 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.15 | 2.9% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $53.06 | 2.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.85 | 2.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.42 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.02 | 1.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.37 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.39 | 1.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.16 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.31 | 1.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.77 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.72 | 0.9% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $16.37 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.09 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.99 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.58 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,045.78 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $298.83 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $203.79 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $169.52 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $166.45 | 10 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $149.79 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $127.49 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $111.17 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $98.89 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.30 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.69 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.59 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.55 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.15 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $53.06 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.39 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 233 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
94 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
119 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
751 | 103 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1334 | 315 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1142 | 229 |
| Pantoprazole Sodium | Pantoprazole Sodium | 809 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 786 | 208 |
| Eliquis | Apixaban | 751 | 103 |
| Gabapentin | Gabapentin | 694 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 689 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 639 | 162 |
| Furosemide | Furosemide | 585 | 118 |
| Lisinopril | Lisinopril | 492 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 465 | 106 |
| Losartan Potassium | Losartan Potassium | 464 | 124 |
| Omeprazole | Omeprazole | 413 | 113 |
| Potassium Chloride | Potassium Chloride | 413 | 96 |
| Sertraline Hcl | Sertraline Hcl | 391 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 118 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 328 | 83 |
| Trazodone Hcl | Trazodone Hcl | 311 | 71 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 306 | 64 |
| Simvastatin | Simvastatin | 286 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 280 | 82 |
| Metformin Hcl | Metformin Hcl | 278 | 84 |
| Pravastatin Sodium | Pravastatin Sodium | 269 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 247 | 69 |
| Jardiance | Empagliflozin | 233 | 45 |
| Tramadol Hcl | Tramadol Hcl | 215 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 56 |
| Lorazepam | Lorazepam | 192 | 37 |
| Clonazepam | Clonazepam | 191 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 190 | 18 |
| Carvedilol | Carvedilol | 188 | 52 |
| Famotidine | Famotidine | 188 | 56 |
| Meloxicam | Meloxicam | 182 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 54 |
| Donepezil Hcl | Donepezil Hcl | 178 | 42 |
| Montelukast Sodium | Montelukast Sodium | 174 | 50 |
| Mirtazapine | Mirtazapine | 170 | 51 |
| Alprazolam | Alprazolam | 167 | 41 |
| Levetiracetam | Levetiracetam | 160 | 24 |
| Lactulose | Lactulose | 154 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 153 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 19 |
| Allopurinol | Allopurinol | 138 | 30 |
| Buspirone Hcl | Buspirone Hcl | 138 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 131 | 51 |
| Januvia | Sitagliptin Phosphate | 129 | 20 |
| Torsemide | Torsemide | 125 | 35 |
| Valsartan | Valsartan | 125 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 29 |
| Trulicity | Dulaglutide | 119 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 27 |
| Finasteride | Finasteride | 118 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 116 | 31 |
| Ozempic | Semaglutide | 116 | 19 |
| Xarelto | Rivaroxaban | 115 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 25 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 112 | 32 |
| Pregabalin | Pregabalin | 111 | 16 |
| Divalproex Sodium | Divalproex Sodium | 108 | 25 |
| Atenolol | Atenolol | 107 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 59 |
| Doxycycline Hyclate | Doxycycline Hyclate | 102 | 91 |
| Fentanyl | Fentanyl | 102 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 100 | 25 |
| Celecoxib | Celecoxib | 100 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 25 |
| Tradjenta | Linagliptin | 100 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 20 |
| Ezetimibe | Ezetimibe | 95 | 30 |
| Brilinta | Ticagrelor | 94 | 11 |
| Lacosamide | Lacosamide | 94 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 91 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 91 | 23 |
| Prednisone | Prednisone | 91 | 61 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 85 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 17 |
| Mounjaro | Tirzepatide | 84 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 20 |
| Clonidine Hcl | Clonidine Hcl | 77 | 29 |
| Baclofen | Baclofen | 76 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 14 |
| Bupropion Xl | Bupropion Hcl | 69 | 21 |
| Novolog Flexpen | Insulin Aspart | 69 | 22 |
| Cephalexin | Cephalexin | 67 | 38 |
| Memantine Hcl | Memantine Hcl | 65 | 15 |
| Propranolol Hcl | Propranolol Hcl | 65 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 13 |
| Entresto | Sacubitril/Valsartan | 63 | 18 |
| Lidocaine | Lidocaine | 63 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 62 | 25 |
| Linzess | Linaclotide | 62 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 60 | 22 |
| Nystatin | Nystatin | 60 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 43 |
| Irbesartan | Irbesartan | 58 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 56 | 54 |
| Spironolactone | Spironolactone | 56 | 20 |
| Olanzapine | Olanzapine | 55 | 16 |
| Diazepam | Diazepam | 53 | 13 |
| Rexulti | Brexpiprazole | 53 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 15 |
| Insulin Aspart Flexpen | Insulin Aspart | 51 | 14 |
| Metformin Hcl Er | Metformin Hcl | 51 | 15 |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Vascepa | Icosapent Ethyl | 49 | 13 |
| Temazepam | Temazepam | 48 | suppressed |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 46 | 11 |
| Midodrine Hcl | Midodrine Hcl | 46 | 19 |
| Aripiprazole | Aripiprazole | 45 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 11 |
| Ibuprofen | Ibuprofen | 44 | 13 |
| Risperidone | Risperidone | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 13 |
| Hydrocortisone | Hydrocortisone | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 37 |
| Xifaxan | Rifaximin | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Sucralfate | Sucralfate | 33 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Corlanor | Ivabradine Hcl | 32 | suppressed |
| Insulin Lispro | Insulin Lispro | 32 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Azithromycin | Azithromycin | 30 | 26 |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 22 |
| Humalog | Insulin Lispro | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 25 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Enulose | Lactulose | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 14 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Exemestane | Exemestane | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Nitroglycerin | Nitroglycerin | 21 | 18 |
| Nystop | Nystatin | 21 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 12 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | suppressed |
| Linezolid | Linezolid | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Klayesta | Nystatin | 15 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 11 |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 12 |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Oxaprozin | Oxaprozin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Repatha Pushtronex | Evolocumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,045.78 · 109 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, INTELLIS ADAPTIVESTIM, JARDIANCE, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, REXULTI, Rybelsus, VERQUVO, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error